NO20041007L - Anvendelse av oksypurin-nukleosider for fremstilling av et farmasoytisk preparat - Google Patents

Anvendelse av oksypurin-nukleosider for fremstilling av et farmasoytisk preparat

Info

Publication number
NO20041007L
NO20041007L NO20041007A NO20041007A NO20041007L NO 20041007 L NO20041007 L NO 20041007L NO 20041007 A NO20041007 A NO 20041007A NO 20041007 A NO20041007 A NO 20041007A NO 20041007 L NO20041007 L NO 20041007L
Authority
NO
Norway
Prior art keywords
preparation
pharmaceutical composition
oxypurine nucleosides
oxypurine
nucleosides
Prior art date
Application number
NO20041007A
Other languages
English (en)
Inventor
Reid W Von Borstel
Michael K Bamat
Bradley M Hiltbrand
James C Butler
Shyam Shirali
Original Assignee
Pro Neuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Neuron Inc filed Critical Pro Neuron Inc
Publication of NO20041007L publication Critical patent/NO20041007L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
NO20041007A 1994-08-12 2004-03-10 Anvendelse av oksypurin-nukleosider for fremstilling av et farmasoytisk preparat NO20041007L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28921494A 1994-08-12 1994-08-12
PCT/US1995/010078 WO1996004923A1 (en) 1994-08-12 1995-08-08 Methods for treating sepsis or inflammatory diseases with oxypurine nucleosides

Publications (1)

Publication Number Publication Date
NO20041007L true NO20041007L (no) 2004-03-10

Family

ID=23110539

Family Applications (3)

Application Number Title Priority Date Filing Date
NO970631A NO970631L (no) 1994-08-12 1997-02-11 Fremgangsmåter for behandling av sepsis eller betennelsessykdommer med oxypurin-nukleosider
NO20016068A NO317199B1 (no) 1994-08-12 2001-12-12 Anvendelse av oksypurin-nukleosider for fremstilling av et farmasoytisk preparat for redusering av inflammasjon i et dyr
NO20041007A NO20041007L (no) 1994-08-12 2004-03-10 Anvendelse av oksypurin-nukleosider for fremstilling av et farmasoytisk preparat

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO970631A NO970631L (no) 1994-08-12 1997-02-11 Fremgangsmåter for behandling av sepsis eller betennelsessykdommer med oxypurin-nukleosider
NO20016068A NO317199B1 (no) 1994-08-12 2001-12-12 Anvendelse av oksypurin-nukleosider for fremstilling av et farmasoytisk preparat for redusering av inflammasjon i et dyr

Country Status (12)

Country Link
US (1) US20040235782A1 (no)
EP (2) EP0771204A4 (no)
JP (2) JPH10507441A (no)
KR (1) KR100290129B1 (no)
AU (1) AU712835B2 (no)
CA (1) CA2197205A1 (no)
FI (1) FI970588A (no)
IL (1) IL114887A0 (no)
NO (3) NO970631L (no)
RU (1) RU2203669C2 (no)
WO (1) WO1996004923A1 (no)
ZA (1) ZA956679B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19818044A1 (de) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
SI2223922T1 (sl) 2000-04-25 2016-04-29 Icos Corporation Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
AU2002358616A1 (en) * 2001-12-07 2003-06-17 Intercell Ag Immunostimulatory oligodeoxynucleotides
DE60324296D1 (de) 2002-09-30 2008-12-04 Bayer Healthcare Ag Kondensierte azolpyrimidinderivate
US6997018B2 (en) 2003-06-02 2006-02-14 Ferro Corporation Method of micro and nano texturing glass
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
JP5718639B2 (ja) 2007-08-16 2015-05-13 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 電離放射線誘発の損傷から哺乳類細胞を保護する方法
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
NZ592880A (en) 2008-11-13 2013-06-28 Gilead Calistoga Llc Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
WO2010123931A1 (en) 2009-04-20 2010-10-28 Calistoga Pharmaceuticals Inc. Methods of treatment for solid tumors
JP2013500257A (ja) 2009-07-21 2013-01-07 ギリアード カリストガ エルエルシー Ｐｉ３ｋインヒビターでの肝障害の処置
WO2011139881A2 (en) * 2010-04-29 2011-11-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compositions containing purine and pyrimidine nucleosides, peptides, and manganese and their uses
AP2014007875A0 (en) 2012-03-05 2014-08-31 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
MX2016008259A (es) 2013-12-20 2016-10-13 Gilead Calistoga Llc Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa.
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
US20230371507A1 (en) * 2020-08-24 2023-11-23 Adama Makhteshim Ltd. Pesticidal compounds and compositions, methods of use and processes of preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU663309C (en) * 1991-02-08 2002-08-08 Pro-Neuron, Inc. Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
US5320846A (en) * 1991-04-17 1994-06-14 New England Deaconess Hospital Corp. Method and composition for testing patients with metabolic depleting diseases

Also Published As

Publication number Publication date
AU712835B2 (en) 1999-11-18
NO970631L (no) 1997-04-11
AU3278495A (en) 1996-03-07
FI970588A0 (fi) 1997-02-12
US20040235782A1 (en) 2004-11-25
NO970631D0 (no) 1997-02-11
WO1996004923A1 (en) 1996-02-22
ZA956679B (en) 1997-02-10
NO20016068L (no) 1997-04-11
EP1157698A3 (en) 2002-05-02
NO20016068D0 (no) 2001-12-12
NO317199B1 (no) 2004-09-13
CA2197205A1 (en) 1996-02-22
KR970704457A (ko) 1997-09-06
RU2203669C2 (ru) 2003-05-10
EP0771204A4 (en) 1999-10-20
KR100290129B1 (ko) 2001-05-15
EP1157698A2 (en) 2001-11-28
JPH10507441A (ja) 1998-07-21
JP2009221221A (ja) 2009-10-01
IL114887A0 (en) 1995-12-08
FI970588A (fi) 1997-04-11
EP0771204A1 (en) 1997-05-07

Similar Documents

Publication Publication Date Title
NO973612L (no) Nytt farmasöytisk preparat
NO943888D0 (no) Farmasöytisk preparat
NO973938L (no) Farmasöytisk preparat av piperidinoalkanolforbindelser
NO941719D0 (no) Farmasöytisk preparat med regulert frigjöringsvirkning
NO921958L (no) Farmasoeytisk preparat
NO922006L (no) Farmasoeytisk preparat
NO20073431L (no) Anvendelse av et antistoff mot interleukin-6-reseptor for fremstilling av et farmasoytisk preparat
NO20021172L (no) Farmasöytisk sammensetning
NO20041007L (no) Anvendelse av oksypurin-nukleosider for fremstilling av et farmasoytisk preparat
NO963032L (no) Oralt preparat
NO973610D0 (no) Nytt farmasöytisk preparat
BR9507768A (pt) Composição farmacêutica
LV11727A (lv) Farmaceitiska kompozicija
FI973280A0 (fi) Farmaseuttinen koostumus
NO973611D0 (no) Nytt farmasöytisk preparat
FI951155A (fi) Farmaseuttinen valmiste
NO20003393D0 (no) FremgangsmÕte for fremstilling av en farmasøytisk formulering
BR9605777A (pt) Composição farmacêutica
NO931014D0 (no) Farmasoeytisk preparat
BR9605131A (pt) Composição farmacêutica
NO179817C (no) Anvendelse av 4,9,11-trien-steroider for fremstilling av et farmasöytisk preparat
NO921691D0 (no) Farmasoeytisk preparat
NO920647L (no) Nasalt farmasoeytisk preparat
KR960016881A (ko) 제약 조성물
SE9402437D0 (sv) Pharmaceutical composition

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application